• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baird Medical to Participate in NASIT 2025 Conference

    1/24/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care
    Get the next $BDMD alert in real time by email

    NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 2025 North American Society for Interventional Thyroidology (NASIT) Conference, taking place January 31 – February 1, 2025, in Washington, D.C.

    NASIT 2024 (Photo Credit: NASIT)

    The NASIT Conference is a premier forum for education, research, and collaboration in thyroid interventions, and Baird Medical is honored to participate in this key industry event. The Company's invitation highlights its growing prominence in the field of microwave ablation while offering a valuable opportunity to engage with global experts, industry leaders, and potential partners.

    As a returning participant, Baird Medical is excited to contribute to discussions on the latest advancements in MWA technology and to collaborate with leading experts in interventional thyroidology. The Company also sees this as an opportunity to gain deeper insights into industry trends, optimize its strategic initiatives, and continue driving innovation and growth in global healthcare.

    During the conference, Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine, will present at the Product Theater, building on his recent milestone of completing 100 MWA cases. His session will provide insights into clinical experiences with MWA in thyroid care.

    Baird Medical remains committed to supporting the ongoing advancement of minimally invasive technologies and collaborating with healthcare professionals to explore innovative approaches in thyroid treatment.

    About Baird Medical

    Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

    About NASIT

    The North American Society for Interventional Thyroidology (NASIT) is the largest multidisciplinary group in the United States dedicated to the field of interventional thyroidology. The society was established to promote the safe integration of ablative thyroid technologies into clinical practice while fostering a collaborative environment that supports education and research in the field. NASIT's mission is twofold: (1) to ensure the safe adoption of ablative technologies in thyroid treatment and (2) to encourage interdisciplinary cooperation among physicians specializing in interventional thyroidology.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

    These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

    Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

    Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

    Contact:

    Eric Huang, PR Liaison

    Baird Medical Investment Holdings Ltd.

    Phone: +1 (888) 508-6228

    Email: [email protected]

     

    Baird Medical (PRNewsfoto/Baird Medical LLC)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-to-participate-in-nasit-2025-conference-302359444.html

    SOURCE BDMD

    Get the next $BDMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BDMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology

    NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United States. This momentum directly supports the Company's strategy to accelerate global growth and expand patient access to advanced, minimally invasive therapies. Reinforcing the Company's market leadership in the western United States, Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada

    2/25/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences

    NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians direct access to its innovative needle-based therapies for thyroid conditions. Baird Medical will join top interventionalists and surgeons to demonstrate how its proprietary technology treats benign nodules without th

    2/19/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital

    NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accelerating patient access to advanced care and solidifies the Company's expanding footprint in key U.S. regional markets.

    2/11/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    SEC Filings

    View All

    SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

    6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    2/10/26 7:59:47 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Baird Medical Investment Holdings Ltd

    424B3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    1/16/26 4:32:46 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Baird Medical Investment Holdings Ltd

    EFFECT - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    1/16/26 12:15:05 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    Leadership Updates

    Live Leadership Updates

    View All

    Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion

    NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the appointment of Mark Saxton as Chief Executive Officer of its U.S. subsidiary. Mr. Saxton is a seasoned medical device executive with more than 25 years of commercial leadership experience, including a decade advancing intravascular RF ablation technologies. He will lead all U.S. operations, including sales, marketing, and market development, as Baird Medical

    12/3/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism. The prestigious academic event was hosted by the China-Japan Friendship Hospital in Beijing, China, from October 17-18, 2025. Chaired by Prof. Ming'an Yu, a leading authority in interventional medicine, the workshop served as a vital platform for the world's foremost experts to share

    10/20/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care